This study was terminated in Bulgaria, in China, in Greece, .... It is testing bifeprunox for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Bifeprunox may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Bifeprunox, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in China, and in Greece.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateMarch 2008
Recruitment status
Terminated
Enrollment listed in the registry
227
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Bulgaria, China, Greece, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00658645
Official title
A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00658645. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 2 sites
BG002
Radnevo
Site status: Not listed — confirm with the team
BG003
Radnevo
Site status: Not listed — confirm with the team
China · 2 sites
CN009
Beijing
Site status: Not listed — confirm with the team
CN008
Beijing
Site status: Not listed — confirm with the team
Greece · 2 sites
GR001
Marousi
Site status: Not listed — confirm with the team
GR003
Tripoli
Site status: Not listed — confirm with the team
Romania · 9 sites
RO004
Brasov
Site status: Not listed — confirm with the team
RO001
Bucharest
Site status: Not listed — confirm with the team
RO002
Bucharest
Site status: Not listed — confirm with the team
RO003
Bucharest
Site status: Not listed — confirm with the team
RO009
Bucharest
Site status: Not listed — confirm with the team
RO008
Iași
Site status: Not listed — confirm with the team
RO005
Piteşti
Site status: Not listed — confirm with the team
RO007
Sibiu
Site status: Not listed — confirm with the team
RO006
Targoviste
Site status: Not listed — confirm with the team
Russia · 13 sites
RU003
Arkhangelsk
Site status: Not listed — confirm with the team
RU017
Chita
Site status: Not listed — confirm with the team
RU001
Moscow
Site status: Not listed — confirm with the team
RU005
Moscow
Site status: Not listed — confirm with the team
RU009
Saint Petersburg
Site status: Not listed — confirm with the team
RU013
Saint Petersburg
Site status: Not listed — confirm with the team
RU012
Saint Petersburg
Site status: Not listed — confirm with the team
RU011
Saint Petersburg
Site status: Not listed — confirm with the team
RU004
Saint Petersburg
Site status: Not listed — confirm with the team
RU010
Saint Petersburg
Site status: Not listed — confirm with the team
RU014
Saint Petersburg
Site status: Not listed — confirm with the team
RU002
Saratov
Site status: Not listed — confirm with the team
RU015
Tomsk
Site status: Not listed — confirm with the team
Taiwan · 2 sites
TW001
Hualien Town
Site status: Not listed — confirm with the team
TW003
Taipei
Site status: Not listed — confirm with the team
Thailand · 4 sites
TH002
Bangkok
Site status: Not listed — confirm with the team
TH001
Bangkok
Site status: Not listed — confirm with the team
TH003
Chiang Mai
Site status: Not listed — confirm with the team
TH004
Chiang Mai
Site status: Not listed — confirm with the team
Ukraine · 4 sites
UA002
Hlevakha
Site status: Not listed — confirm with the team
UA001
Kyiv
Site status: Not listed — confirm with the team
UA013
Kyiv
Site status: Not listed — confirm with the team
UA012
Luhansk
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Bifeprunox, Placebo, Quetiapine. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by H. Lundbeck A/S, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
